Nice! I think this is the first real world data we have on periop complications in the setting of #GLP1s for #diabetes
👉GLP1 associated with LOWER risk of peri/post op decelerated gastric emptying and antiemetic use compared with non-users
👉No diff in risk for: ileus within 7

If there a risk of periop compli w #GLP1a
AACE Endocrine Society ADA Professional Publications American Diabetes Association - DiabetesPro

Daniel J Drucker Beverly G. Tchang, MD Miller Medicine Cristobal Morales mariagrazia girone Prof Kamlesh Khunti
Georgia Center for Diabetes Translation Research Javier Escalada #Yoelijoendocrino Ted Kyle Mohammed K Ali Rozalina (Grubina) McCoy, MD MS

…ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

Novo's new trial on alcohol-related liver disease will look at whether Wegovy + other drugs affect alcohol intake

Anecdotes suggest GLP-1 drugs can curb substance consumption, but companies have up until now not studied this. w Isa Cueto
statnews.com/2024/05/14/weg…

You rarely see Democrats and Republicans agree on an issue, so it’s particularly impactful that majorities agree on this. #Medicare should cover #GLP1s for #obesity .

healthline.com/health-news/ho… Healthline KFF Health News

New data at #ECO2024 on #semaglutide heart health benefits and long-term weight outcomes present a compelling picture of clinical benefits.
conscienhealth.org/2024/05/long-t…

Misclassification of weight status based on BMI if the reference was total fat mass, #obesity #ECO2024

I just registered for the Your Weight Matters virtual conference!

Always hugely appreciative of OAC and everything they do for patient #education and #advocacy

buff.ly/4baQMJR

#free #webinar #obesity #medicine

I'm looking forward to OAC #YourWeightMattersVirtual conference ywmconvention.com/ywm-virtual/sc… on 5/18-5/19

I'm covering a lot of ground in 20 minutes, including how #obesity is caused by both genetics and the environment. Here's a teaser slide:

Regarding new data on #cancer and #obesity at #ECO2024 , EASO_President says “This is a really strong, large-scale analysis…If this does not cause concern for health policy makers it is difficult to see what will.”
More of same is not good enough.
conscienhealth.org/2024/05/eco202…

Registration is open for ObesityWeek Nov 3-6, 2024 #OW2024

I will be speaking at the pre-conference ‘Foundations of Obesity Care’ course (Nov 2-3) on Obesity Practice Management and joining colleagues in a Case Learning Session.

Join Us: obesityweek.org

I just registered for ObesityWeek November 3-6, 2024!

See you on :
👉11/3 for my Clinical Consultations roundtable
👉11/5 as I debate Philip Schauer, MD on anti #obesity meds vs bariatric surgery 😬😅

obesityweek.org #OW2024 The Obesity Society

Are anti #obesity #medications forever?

Not necessarily. If the #obesity is caused by an external factor that is removed, you may not need medication to correct the pathophys

eg) Drug-induced #weightgain ➡️stop the drug

#unpopularopinion

Beverly G. Tchang, MD And I’m going to keep pushing to not call these “weight loss drugs”, and instead to call them anti-obesity medications as you are!

Pay attention! We at Tri-state Obesity Society society will be announcing an exciting new #obesity #education #webinar series that will be *different* from any other you've attended before

I recommend signing up for our General Membership (free) plan to be In the Know when we announce!

Lately been thinking more on the complexity of #healthcare delivery

It should be frictionless

But #tech in healthcare has historically been the opposite, at least for clinicians #Epic

Glad to see tech easing pain points Ro ro.co/os/ Z Reitano

I'm going to keep pushing for this categorization of anti #obesity #medicine

❌Some experts say we're on 2nd gen AOMs.
✅I argue we're on 3rd gen

Is it semantics? No.

It's important to recognize the long history of obesity. This is not a fad. Not a trend. It didn't come out

Was at #AACE2024 for a hot second and ran into this main character

Looking forward to the panel on past present and future of #obesity #medicine Karl Nadolsky Jaime Almandoz, MD MBA FTOS AACE

In today's world of severe #access issues of #GLP1 and sometimes insulin #shortages , I am worried more about DKA in my pts with #diabetes

New guidelines from AACE lower the glucose threshold for DKA diagnosis, recognizing that it can occur at any glucose levels (due to SGLT2i)